Literature DB >> 27931650

Effect of non-adrenergic vasopressors on macro- and microvascular coupling in distributive shock.

M Hessler1, T G Kampmeier2, S Rehberg3.   

Abstract

The present review initially describes the rationale for the use of non-adrenergic vasopressors in the treatment of distributive shock and then provides an overview of the individual vasopressin-receptor agonists, namely arginine vasopressin, terlipressin, and selepressin. Following a brief summary of their current use in clinical practice, the present review focuses on the influence of vasopressin-receptor agonists on macro- and microvascular coupling, also referred to as hemodynamic coherence. On the basis of the current evidence from experimental and clinical studies, vasopressin-receptor agonists do not negatively influence macro- and microvascular coupling as compared to the standard therapy with norepinephrine, when used in established treatment regimes. A higher selectivity for the V1a-receptor seems to be beneficial; however, future clinical trials are warranted to verify this assumption. Notably, the optimal treatment regime for non-adrenergic vasopressors with respect to compound, dose, and timing still needs to be defined. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  arginine vasopressin; hemodynamic coherence; microcirculation; selepressin; septic shock; terlipressin; vasoplegic shock

Mesh:

Substances:

Year:  2016        PMID: 27931650     DOI: 10.1016/j.bpa.2016.10.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  2 in total

1.  Terlipressin as a first choice in septic shock-not yet.

Authors:  Daniel Lima Rocha; Fabio Tanzillo Moreira; Ary Serpa Neto
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

2.  Clinical Efficiency of Vasopressin or Its Analogs in Comparison With Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-Analysis.

Authors:  Ren-Qi Yao; De-Meng Xia; Li-Xue Wang; Guo-Sheng Wu; Yi-Bing Zhu; Hong-Qiang Zhao; Qi Liu; Zhao-Fan Xia; Chao Ren; Yong-Ming Yao
Journal:  Front Pharmacol       Date:  2020-05-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.